A Study of Tirzepatide (LY3298176) Once a Week Versus Insulin Glargine Once a Day in Participants With Type 2 Diabetes and Increased Cardiovascular Risk

NCT ID: NCT03730662

Last Updated: 2022-02-14

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

2002 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-11-20

Study Completion Date

2021-04-22

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of the trial is to assess the efficacy and safety of tirzepatide taken once a week to insulin glargine taken once daily in participants with type 2 diabetes and increased cardiovascular risk. The study will last about 108 weeks and may include up to 30 visits.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Type 2 Diabetes Mellitus

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

5 mg Tirzepatide

5 milligrams (mg) tirzepatide administered subcutaneously (SC) once a week.

Group Type EXPERIMENTAL

Tirzepatide

Intervention Type DRUG

Administered SC.

10 mg Tirzepatide

10 mg tirzepatide administered SC once a week.

Group Type EXPERIMENTAL

Tirzepatide

Intervention Type DRUG

Administered SC.

15 mg Tirzepatide

15 mg tirzepatide administered SC once a week.

Group Type EXPERIMENTAL

Tirzepatide

Intervention Type DRUG

Administered SC.

Insulin Glargine

Insulin glargine administered SC once a day. Doses were individualized and titrated according to protocol-defined targets.

The starting dose of insulin glargine was 10 IU/day at bedtime, titrated to a FBG \<100 mg/dL, following a treat-to-target (TTT) algorithm.

Group Type ACTIVE_COMPARATOR

Insulin Glargine

Intervention Type DRUG

Administered SC

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Tirzepatide

Administered SC.

Intervention Type DRUG

Insulin Glargine

Administered SC

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

LY3298176

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Participants must:

* Have been diagnosed with type 2 diabetes mellitus (T2DM)
* Have HbA1c between ≥7.5% and ≤10.5%
* Be on stable treatment with unchanged dose of at least 1 and no more than 3 types of oral antihyperglycemic drugs, which may only include metformin, SGLT-2 inhibitors, and/or sulfonylureas for at least 3 months before screening
* Have increased risk for cardiovascular (CV) events
* Be of stable weight (± 5%)
* Have a BMI ≥25 kilograms per meter squared (kg/m2) at screening

Exclusion Criteria

Participants must not:

* Have type 1 diabetes mellitus
* Have had chronic or acute pancreatitis any time prior to study entry
* Have proliferative diabetic retinopathy or diabetic maculopathy or nonproliferative diabetic retinopathy requiring immediate or urgent treatment
* Have disorders associated with slowed emptying of the stomach, or have had any stomach surgeries for the purpose of weight loss
* Have acute or chronic hepatitis, signs and symptoms of any other liver disease, or blood alanine transaminase (ALT) enzyme level \>3.0 times the upper limit of normal (ULN) for the reference range, as determined by the central laboratory. Participants with nonalcoholic fatty liver disease (NAFLD) are eligible for participation in this trial only if there ALT level is ≤3.0 the ULN for the reference range
* Have had a heart attack, stroke, or hospitalization for congestive heart failure in the past 2 months
* Have a personal or family history of medullary thyroid carcinoma or personal history of multiple endocrine neoplasia syndrome type 2
* Have been taking any other diabetes medicines other than metformin, SGLT-2 inhibitors, and/or sulfonylureas during the last 3 months
* Have been taking weight loss drugs, including over-the-counter medications during the last 3 months
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Eli Lilly and Company

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)

Role: STUDY_DIRECTOR

Eli Lilly and Company

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Advanced Research Center

Anaheim, California, United States

Site Status

Valley Clinical Trials, Inc.

Covina, California, United States

Site Status

Marin Endocrine Associates

Greenbrae, California, United States

Site Status

National Research Institute

Huntington Park, California, United States

Site Status

Scripps Whittier Diabetes Institute

La Jolla, California, United States

Site Status

First Valley Medical Group

Lancaster, California, United States

Site Status

National Research Institute

Los Angeles, California, United States

Site Status

Catalina Research Institute, LLC

Montclair, California, United States

Site Status

Monterey Endocrine & Diabetes Institute, Inc.

Monterey, California, United States

Site Status

Valley Clinical Trials, Inc.

Northridge, California, United States

Site Status

Desert Medical Group Inc

Palm Springs, California, United States

Site Status

Havana Research Institute

Pasadena, California, United States

Site Status

Western University of Health Sciences

Pomona, California, United States

Site Status

LCGK Research

San Carlos, California, United States

Site Status

Olive View Medical Center

Sylmar, California, United States

Site Status

University Clinical Investigators, Inc.

Tustin, California, United States

Site Status

Touro University

Vallejo, California, United States

Site Status

Coastal Metabolic Research Centre

Ventura, California, United States

Site Status

Diablo Clinical Research

Walnut Creek, California, United States

Site Status

Chase Medical Research, LLC

Waterbury, Connecticut, United States

Site Status

ALL Medical Research, LLC

Cooper City, Florida, United States

Site Status

Advanced Pharma Research

Cutler Bay, Florida, United States

Site Status

South Florida Wellness & Clinical Research Institute

Margate, Florida, United States

Site Status

Suncoast Research Group, LLC

Miami, Florida, United States

Site Status

New Horizon Research Center

Miami, Florida, United States

Site Status

Clinical Neuroscience Solutions Inc

Orlando, Florida, United States

Site Status

Progressive Medical Research

Port Orange, Florida, United States

Site Status

Primary Care Specialists, LLC

Atlanta, Georgia, United States

Site Status

Rocky Mountain Diabetes and Osteoporosis Center

Idaho Falls, Idaho, United States

Site Status

Solaris Clinical Research

Meridian, Idaho, United States

Site Status

Saltzer Medical Group. P.A.

Nampa, Idaho, United States

Site Status

Northwestern Feinberg School of Medicine

Chicago, Illinois, United States

Site Status

NorthShore University HealthSystem

Skokie, Illinois, United States

Site Status

University of Iowa Hospital & Clinic

Iowa City, Iowa, United States

Site Status

Iowa Diabetes Research

West Des Moines, Iowa, United States

Site Status

Cotton O'Neil Diabetes and Endocrinology Center

Topeka, Kansas, United States

Site Status

Robley Rex VAMC

Louisville, Kentucky, United States

Site Status

NECCR PrimaCare Research, LLC

Fall River, Massachusetts, United States

Site Status

AA Medical Research Center

Flint, Michigan, United States

Site Status

Troy Internal Medicine, PC

Troy, Michigan, United States

Site Status

Clinical Research Professionals

Chesterfield, Missouri, United States

Site Status

Glacier View Research Institute

Kalispell, Montana, United States

Site Status

Montana Medical Research, Inc

Missoula, Montana, United States

Site Status

Palm Research Center

Las Vegas, Nevada, United States

Site Status

Palm Research Center

Las Vegas, Nevada, United States

Site Status

Southern New Hampshire Diabetes and Endocrinology

Nashua, New Hampshire, United States

Site Status

PharmQuest

Greensboro, North Carolina, United States

Site Status

Lillestol Research LLC

Fargo, North Dakota, United States

Site Status

Rapid Medical Research Inc

Cleveland, Ohio, United States

Site Status

Ohio State Univ College Of Medicine

Columbus, Ohio, United States

Site Status

Aventiv Research

Columbus, Ohio, United States

Site Status

Intend Research

Norman, Oklahoma, United States

Site Status

The Corvallis Clinic P.C.

Corvallis, Oregon, United States

Site Status

Oregon Health and Science University

Portland, Oregon, United States

Site Status

Heritage Valley Medical Group, Inc.

Beaver, Pennsylvania, United States

Site Status

Capital Area Research

Camp Hill, Pennsylvania, United States

Site Status

Detweiler Family Medicine

Lansdale, Pennsylvania, United States

Site Status

Capital Area Research

Newport, Pennsylvania, United States

Site Status

Parkside Family Medical

Philadelphia, Pennsylvania, United States

Site Status

Preferred Primary Care Physicians- Bower Hill

Pittsburgh, Pennsylvania, United States

Site Status

Mountain View Clinical Research, Inc.

Greer, South Carolina, United States

Site Status

The Research Center of the Upstate

Mauldin, South Carolina, United States

Site Status

Holston Medical Group Clinical Research

Kingsport, Tennessee, United States

Site Status

New Phase Research & Development

Knoxville, Tennessee, United States

Site Status

Dallas Diabetes Endocrine Center

Dallas, Texas, United States

Site Status

PCP for Life

Houston, Texas, United States

Site Status

BFHC Research

San Antonio, Texas, United States

Site Status

Consano Clinical Research

Shavano Park, Texas, United States

Site Status

Martin Diagnostic Clinic

Tomball, Texas, United States

Site Status

Alpine Research Organization

Farmington, Utah, United States

Site Status

Burke Internal Medicine & Research

Burke, Virginia, United States

Site Status

Private: Dr. Larry Stonesifer

Federal Way, Washington, United States

Site Status

Capital Clinical Research Center

Olympia, Washington, United States

Site Status

Walla Walla Clinic

Walla Walla, Washington, United States

Site Status

Centro de Investigaciones Metabólicas (CINME)

CABA, Buenos Aires, Argentina

Site Status

Mautalen Salud e Investigación - Servicio de Endocrinología

CABA, Buenos Aires, Argentina

Site Status

Investigaciones Medicas IMOBA S.R.L.

Caba, Buenos Aires, Argentina

Site Status

CEDIC-Centro de Investigaciones Clinicas

Caba, Buenos Aires, Argentina

Site Status

CEMEDIC

CABA, Buenos Aires, Argentina

Site Status

Centro Medico Dr Laura Maffei Investigacion Clinica Aplicada

Ciudad Autonoma de Buenos Aire, Buenos Aires, Argentina

Site Status

Centro de Investigacion y Prevencion Cardiovascular (CIPREC)

Ciudad Autonoma de, Buenos Aires, Argentina

Site Status

CIPADI

Godoy Cruz, Mendoza Province, Argentina

Site Status

AXISMED SRL - Bioclinica Research Network

Buenos Aires, , Argentina

Site Status

Centro Médico Viamonte

Ciudad Autonoma de Buenos Aire, , Argentina

Site Status

Instituto Centenario

Ciudad Autonoma de Buenos Aire, , Argentina

Site Status

Cemediab - Centro Médico Diabetológico Dr. Alejandro Chertkoff

Ciudad Autonoma de Buenos Aire, , Argentina

Site Status

Centro Diabetologico Dr Waitman

Córdoba, , Argentina

Site Status

Centro Medico Privado San Vicente Diabetes

Córdoba, , Argentina

Site Status

Cent Priva Especiali Médicas Ambulatorias Inve Clin CEMAIC

Córdoba, , Argentina

Site Status

Paratus Clinical Blacktown Clinic

Blacktown, New South Wales, Australia

Site Status

Campbelltown Medical & Dental Centre

Campbelltown, New South Wales, Australia

Site Status

Paratus Clinical Kanwal Clinic

Kanwal, New South Wales, Australia

Site Status

The AIM Centre

Merewether, New South Wales, Australia

Site Status

Royal North Shore Hospital

St Leonards, New South Wales, Australia

Site Status

CORE Research Group Pty Ltd

Brisbane, Queensland, Australia

Site Status

Morayfield Medical and Dental Centre

Morayfield, Queensland, Australia

Site Status

AusTrials Pty Ltd

Sherwood, Queensland, Australia

Site Status

Victoria Point Medical and Dental Centre

Victoria Point, Queensland, Australia

Site Status

GP Plus Marion

Oaklands Park, South Australia, Australia

Site Status

Eastern Clinical Research Unit

Box Hill, Victoria, Australia

Site Status

Forest Hill Medical and Dental Centre

Forest Hill, Victoria, Australia

Site Status

Barwon Health - The Geelong Hospital

Geelong, Victoria, Australia

Site Status

Royal Melbourne Hospital

Parkville, Victoria, Australia

Site Status

Fremantle Hospital

Fremantle, Western Australia, Australia

Site Status

Instituto de Ensino e Pesquisa Clinica do Ceara

Fortaleza, Ceará, Brazil

Site Status

Cedoes Centro Diagnostico Pequisa Osteoporose E Santo Ltd

Vitória, Espírito Santo, Brazil

Site Status

Centro de Pesquisa Clinica do Brasil

Brasília, Federal District, Brazil

Site Status

Centro de Diabetes Curitiba

Curitiba, Paraná, Brazil

Site Status

CCBR Brasil Centro de Analises e Pesquisas Clínicas LTDA

Rio de Janeiro, Rio de Janeiro, Brazil

Site Status

CPQuali Pesquisa Clínica Ltda.

São Paulo, São Paulo, Brazil

Site Status

Cpclin Centro de Pesquisas Clinicas

São Paulo, São Paulo, Brazil

Site Status

Centro de Pesq. em Diabetes e Doencas Endocrino Metabol.

Fortaleza, , Brazil

Site Status

Dr. Consulta Clínica Médica LTDA

São Paulo, , Brazil

Site Status

LMC Manna Research

Calgary, Alberta, Canada

Site Status

C-Health Diabetes and Endocrinology Clinic Calgary

Calgary, Alberta, Canada

Site Status

Synergy Medical Research

Sherwood Park, Alberta, Canada

Site Status

LMC Endocrinology Centres Ltd.

Barrie, Ontario, Canada

Site Status

LMC Endocrinology Centers Brampton

Brampton, Ontario, Canada

Site Status

Aggarwal and Associates Ltd

Brampton, Ontario, Canada

Site Status

LMC Endocrinology Centres Ltd.

Concord, Ontario, Canada

Site Status

Medicor Research Inc

Greater Sudbury, Ontario, Canada

Site Status

Milestone Research Inc.

London, Ontario, Canada

Site Status

LMC Endocrinology Centres Ltd.

Nepean, Ontario, Canada

Site Status

Bluewater Clinical Research Group Inc

Sarnia, Ontario, Canada

Site Status

Canadian Centre for Research on Diabetes

Smiths Falls, Ontario, Canada

Site Status

Manna Research, Inc.

Stoney Creek, Ontario, Canada

Site Status

LMC Endocrinology Centres Ltd.

Toronto, Ontario, Canada

Site Status

Sameh Fikry Medicine Professional Corporation

Waterloo, Ontario, Canada

Site Status

Q & T Research Outaouais

Gatineau, Quebec, Canada

Site Status

Centre De Recherche Clinique De Laval

Laval, Quebec, Canada

Site Status

Manna Research (Quebec)

Lévis, Quebec, Canada

Site Status

LMC Endocrinology Centres Ltd.

Saint-Laurent, Quebec, Canada

Site Status

Iatriko Palaiou Falirou, Medical Center

Palaió Fáliro, Athens, Greece

Site Status

Thermi Clinic

Thermi, Thessaloniki, Greece

Site Status

University General Hospital of Larissa

Larissa, , Greece

Site Status

AHEPA Hospital

Thessaloniki, , Greece

Site Status

Euromedica - General Clinic of Thessaloniki

Thessaloniki, , Greece

Site Status

Ha'Emek Medical Center

Afula, , Israel

Site Status

Soroka Medical Center

Beersheba, , Israel

Site Status

Rambam Medical Center

Haifa, , Israel

Site Status

Wolfson Medical Center

Holon, , Israel

Site Status

Hadassah Medical Center

Jerusalem, , Israel

Site Status

Rabin Medical Center

Petah Tikva, , Israel

Site Status

Sheba Medical Center

Ramat Gan, , Israel

Site Status

Sakhnin Community Clinic, Clalit Health Services

Sakhnin, , Israel

Site Status

Tel Aviv Sourasky Medical Center

Tel Aviv, , Israel

Site Status

Instituto Jalisciense de Investigacion en Diabetes y Obesida

Guadalajara, Jalisco, Mexico

Site Status

Diseno y Planeacion en Investigacion Medica S.C.

Guadalajara, Jalisco, Mexico

Site Status

Unidad Medica para la Salud Integral (UMSI)

Monterrey, Nuevo León, Mexico

Site Status

St. Lucas Clinical Research Center

Merida, State of Mexico, Mexico

Site Status

Centro de Estudios de Investigacion Metabolicos y Cardiovasc

Tampico, Tamaulipas, Mexico

Site Status

Investigacion en Salud y Metabolismo S.C

Chihuahua City, , Mexico

Site Status

Centralny Szpital Kliniczny MSWiA Klinika Dermatologiczna

Warsaw, Masovian Voivodeship, Poland

Site Status

Poradnia Diabetologiczna SN ZOZ Lege Artis

Bialystok, , Poland

Site Status

NZOZ Diab-Endo-Met

Krakow, , Poland

Site Status

Centrum Terapii Wspolczesnej J.M. Jasnorzewska S.K.A.

Lodz, , Poland

Site Status

NZOZ CenterMed Lublin

Lublin, , Poland

Site Status

Gabinety Terpa

Lublin, , Poland

Site Status

NZOZ Przychodnia Specjalistyczna MEDICA

Lublin, , Poland

Site Status

Praktyka Lekarska

Poznan, , Poland

Site Status

Nzoz Neuro - Kard

Poznan, , Poland

Site Status

NZOZ Przychodnia Specjalistyczna Henryk RudzkiAndrzej Wittek

Ruda Śląska, , Poland

Site Status

Woj. Zesp. Spec. Opieki Zdrowotnej

Wroclaw, , Poland

Site Status

Manati Center for Clinical Research Inc

Manatí, PR, Puerto Rico

Site Status

Ponce School of Medicine CAIMED Center

Ponce, PR, Puerto Rico

Site Status

Research and Cardiovascular Corp.

Ponce, PR, Puerto Rico

Site Status

University Of Puerto Rico

Rio Pedras, PR, Puerto Rico

Site Status

GCM Medical Group PSC

San Juan, PR, Puerto Rico

Site Status

Consultorio Medico

San Juan, PR, Puerto Rico

Site Status

Emanuelli Research & Development Center, LLC

Arecibo, , Puerto Rico

Site Status

SC Gama Diamed SRL

Mangalia, Constanța County, Romania

Site Status

Spitalul Judetean de Urgenta Satu Mare

Satu Mare, Jud Satu-Mare, Romania

Site Status

CMI DNBM Dr. Pop Lavinia

Baia Mare, Maramureş, Romania

Site Status

Cosamext SRL

Târgu Mureş, Mureș County, Romania

Site Status

Centrul Medical Dr. Negrisanu

Timișoara, Timiș County, Romania

Site Status

Centrul Medical de Diagnostic si Tratament Ambulatoriu Neomed SRL

Brasov, , Romania

Site Status

Cabinetul Medical Nicodiab SRL

Bucharest, , Romania

Site Status

SC Nutrilife SRL

Bucharest, , Romania

Site Status

Milena Sante SRL

Galati, , Romania

Site Status

Regional Clinical Hospital

Saratov, Russian Federation, Russia

Site Status

Arkhangelsk the first city clinical hospital

Arkhangelsk, , Russia

Site Status

FSBI Endocrinological Research Center of the MOH of the ROF

Moscow, , Russia

Site Status

Novosibirsk Regional Clinical Hospital

Novosibirsk, , Russia

Site Status

Ryazan Regional Clinincal Cardiology Dispensary

Ryazan, , Russia

Site Status

City Hospital of Saint Martyr Elizabeth

Saint Petersburg, , Russia

Site Status

Medical Military Academy

Saint Petersburg, , Russia

Site Status

City Consultative and Diagnostic Center

Saint Petersburg, , Russia

Site Status

SPb GUZ "Diagnostic Center #85"

Saint Petersburg, , Russia

Site Status

Research & Practice Ltd

Yaroslavl, , Russia

Site Status

Human care s.r.o.

Košice, Slovak Republic, Slovakia

Site Status

MediVet s.r.o.

Malacky, Slovak Republic, Slovakia

Site Status

Areteus s.r.o.

Trebišov, Slovak Republic, Slovakia

Site Status

DIA-MED CENTRUM s.r.o.

Púchov, , Slovakia

Site Status

Tatratrial s.r.o.

Rožňava, , Slovakia

Site Status

MEDI-DIA s.r.o.

Sabinov, , Slovakia

Site Status

Hospital Universitario Marques De Valdecilla

Santander, Cantabria, Spain

Site Status

Hospital Universitario Quiron Madrid

Pozuelo de Alarcón, Madrid, Spain

Site Status

Hospital de la Ribera

Alzira, Valencia, Spain

Site Status

Complexo Hospitalario Universitario A Coruña, CHUAC

A Coruña, , Spain

Site Status

Instituto de Ciencias medicas

Alicante, , Spain

Site Status

Centro Periférico de Especialidades Bola Azul

Almería, , Spain

Site Status

Hospital Quironsalud Barcelona- END

Barcelona, , Spain

Site Status

Hospital Clinico Universitario San Cecilio

Granada, , Spain

Site Status

Centro Especialidades San Jose Obrero (Barbarela)

Málaga, , Spain

Site Status

Clinica Juaneda

Palma de Mallorca, , Spain

Site Status

Clinica Nuevas Tecnologias en Diabetes y Endocrinologia

Seville, , Spain

Site Status

Hospital Universitario Virgen Macarena

Seville, , Spain

Site Status

Cardinal Tien Hospital

Sindian City, Taipei, Taiwan

Site Status

Chang Gung Memorial Hospital - Kaohsiung

Kaohsiung City, , Taiwan

Site Status

Chung Shan Medical University Hospital

Taichung, , Taiwan

Site Status

China Medical University Hospital

Taichung, , Taiwan

Site Status

Kuang Tien General Hospital

Taichung County, , Taiwan

Site Status

National Cheng Kung University Hospital

Tainan City, , Taiwan

Site Status

Chi-Mei Medical Center

Tainan City, , Taiwan

Site Status

National Taiwan University Hospital

Taipei, , Taiwan

Site Status

Taipei Veterans General Hospital

Taipei, , Taiwan

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Argentina Australia Brazil Canada Greece Israel Mexico Poland Puerto Rico Romania Russia Slovakia Spain Taiwan

References

Explore related publications, articles, or registry entries linked to this study.

De Block C, Peleshok J, Wilding JPH, Kwan AYM, Rasouli N, Maldonado JM, Wysham C, Liu M, Aleppo G, Benneyworth BD. Post Hoc Analysis of SURPASS-1 to -5: Efficacy and Safety of Tirzepatide in Adults with Type 2 Diabetes are Independent of Baseline Characteristics. Diabetes Ther. 2025 Jan;16(1):43-71. doi: 10.1007/s13300-024-01660-0. Epub 2024 Nov 12.

Reference Type DERIVED
PMID: 39531161 (View on PubMed)

Boye KS, Sapin H, Dong W, Williamson S, Lee CJ, Thieu VT. Improved Glycaemic and Weight Management Are Associated with Better Quality of Life in People with Type 2 Diabetes Treated with Tirzepatide. Diabetes Ther. 2023 Nov;14(11):1867-1887. doi: 10.1007/s13300-023-01457-7. Epub 2023 Sep 5.

Reference Type DERIVED
PMID: 37668888 (View on PubMed)

Boye KS, Thieu VT, Sapin H, Lee CJ, Lando LF, Brown K, Bray R, Wiese RJ, Patel H, Rodriguez A, Yu M. Patient-Reported Outcomes in People with Type 2 Diabetes Receiving Tirzepatide in the SURPASS Clinical Trial Programme. Diabetes Ther. 2023 Nov;14(11):1833-1852. doi: 10.1007/s13300-023-01451-z. Epub 2023 Aug 1.

Reference Type DERIVED
PMID: 37526908 (View on PubMed)

Heerspink HJL, Sattar N, Pavo I, Haupt A, Duffin KL, Yang Z, Wiese RJ, Tuttle KR, Cherney DZI. Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial. Lancet Diabetes Endocrinol. 2022 Nov;10(11):774-785. doi: 10.1016/S2213-8587(22)00243-1. Epub 2022 Sep 21.

Reference Type DERIVED
PMID: 36152639 (View on PubMed)

Sattar N, McGuire DK, Pavo I, Weerakkody GJ, Nishiyama H, Wiese RJ, Zoungas S. Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis. Nat Med. 2022 Mar;28(3):591-598. doi: 10.1038/s41591-022-01707-4. Epub 2022 Feb 24.

Reference Type DERIVED
PMID: 35210595 (View on PubMed)

Del Prato S, Kahn SE, Pavo I, Weerakkody GJ, Yang Z, Doupis J, Aizenberg D, Wynne AG, Riesmeyer JS, Heine RJ, Wiese RJ; SURPASS-4 Investigators. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet. 2021 Nov 13;398(10313):1811-1824. doi: 10.1016/S0140-6736(21)02188-7. Epub 2021 Oct 18.

Reference Type DERIVED
PMID: 34672967 (View on PubMed)

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Related Links

Access external resources that provide additional context or updates about the study.

https://trials.lillytrialguide.com/en-US/trial/740VpRcJPiyieyyWGYO2ao

A Study of Tirzepatide (LY3298176) Once a Week Versus Insulin Glargine Once a Day in Participants With Type 2 Diabetes and Increased Cardiovascular Risk

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

I8F-MC-GPGM

Identifier Type: OTHER

Identifier Source: secondary_id

2018-002618-11

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

17072

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

A Study for Patients With Type 2 Diabetes
NCT01027871 COMPLETED PHASE2
A Study for Patients With Type 1 Diabetes
NCT01049412 COMPLETED PHASE2